News

Iclaprim, which is a diaminopyrimidine antibiotic, met its primary endpoint and was found to be well tolerated during the phase 3 clinical trial dubbed REVIVE-2. Featuring 600 ABSSSI

The over-subscribed round brings the company's total capital raised to more than $80 million. Recursion augments traditional drug discovery approaches, most prominently phenotypic screening, with artificial intelligence (AI).

Under the deal, the partnership will develop CytomX Probody T-cell engaging bispecific against the epidermal growth factor receptor (EGFR), a validated oncology target expressed on multiple human cancer

The company received series E financing, which was supported by existing investors such as dievini Hopp Biotech, Wellington Partners and AT Impf GmbH, as well as by new

Jenner Institute of Oxford University and Vaccitech, which was spun out of it, had developed the new flu vaccine. Over 10,000 people aged 65 and over will be

The latest agreement with Bayer extends their access to X-Chem’s DEX™ technology by including the synthesis of custom Bayer DNA-Encoded Libraries and expanding the number of potential programs.

On August 28, 2017, Gilead and Kite announced that Kite, Gilead and Purchaser had signed a definitive merger agreement pursuant to which a tender offer would be made.

Adcetris is an antibody-drug conjugate (ADC) directed to CD30, a determining marker of Hodgkin lymphoma. The ADC includes an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to

An anti-von Willebrand factor (vWF) nanobody, Caplacizumab met both the primary endpoint and key secondary endpoints of the phase 3 trial, dubbed HERCULES. The late-stage trial evaluated it against